Traws Pharma (TRAW) Stock Price, News & Analysis

Company Overview

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Key Stats

• Today's Range: $4.32 to $4.75
• 50-Day Range: $4.49 to $7.50
• 52-Week Range: $4.16 to $27.50
• Volume: 828 shs
• Average Volume: 5,868 shs
• Market Capitalization: $8.69 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Traws Pharma Stock Analysis - MarketRank™

Traws Pharma scored higher than 17% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Traws Pharma.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Traws Pharma are expected to grow in the coming year, from ($146.00) to ($33.75) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Traws Pharma is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Traws Pharma is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.25% of the float of Traws Pharma has been sold short.

Short Interest Ratio / Days to Cover

Traws Pharma has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Traws Pharma has recently decreased by 23.71%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Traws Pharma does not currently pay a dividend.

Dividend Growth

Traws Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.25% of the float of Traws Pharma has been sold short.

Short Interest Ratio / Days to Cover

Traws Pharma has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Traws Pharma has recently decreased by 23.71%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: -0.05

News Sentiment

Traws Pharma has a news sentiment score of -0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Traws Pharma this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for TRAW on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Traws Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.10% of the stock of Traws Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 7.95% of the stock of Traws Pharma is held by institutions.

TRAW Stock Analysis - Frequently Asked Questions

How have TRAW shares performed this year?

Traws Pharma's stock was trading at $7.50 at the beginning of the year. Since then, TRAW shares have decreased by 36.7% and is now trading at $4.75.
View the best growth stocks for 2024 here.

How do I buy shares of Traws Pharma?

Shares of TRAW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Traws Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Traws Pharma investors own include Clearside Biomedical (CLSD), Evofem Biosciences (EVFM), Nikola (NKLA), Palatin Technologies (PTN), Sirius XM (SIRI), Adverum Biotechnologies (ADVM) and Aptinyx (APTX).

Company Calendar

• Today: 11/20/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:TRAW
• Previous Symbol: NASDAQ:TRAW
• CUSIP: N/A
• CIK: 1130598
• Web: www.onconova.com
• Phone: 267-759-3680
• Fax: 267-759-3681
• Employees: 17
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($141.56)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-18,950,000.00
• Net Margins: -62,294.25%
• Pretax Margin: -62,294.25%
• Return on Equity: -144.95%
• Return on Assets: -822.38%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.07
• Quick Ratio: 1.07

Sales & Book Value

• Annual Sales: $230,000.00
• Price / Sales: 35.72
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $12.70 per share
• Price / Book: 0.35

Miscellaneous

• Outstanding Shares: 1,830,000
• Free Float: 1,533,000
• Market Cap: $8.22 million
• Optionable: Optionable
• Beta: 1.41